JAZZ’s Xywav Gets Orphan Drug Exclusivity for Hypersomnia

Posted byZacks Equity Research Leave a comment on JAZZ’s Xywav Gets Orphan Drug Exclusivity for Hypersomnia

The FDA bestows an Orphan Drug Exclusivity to Jazz’s (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.

Leave a comment

Your email address will not be published. Required fields are marked *